Vasopressin deficiency: a hypothesized driver of both social impairment and fluid imbalance in autism spectrum disorder
- PMID: 38454082
- PMCID: PMC11380037
- DOI: 10.1038/s41380-024-02497-6
Vasopressin deficiency: a hypothesized driver of both social impairment and fluid imbalance in autism spectrum disorder
Conflict of interest statement
LC, NG, and EHS have no interests to declare. AYH declares consulting fees from Quadrant Bio, IAMA therapeutics, and Beaming Health. AYH and KJP are receiving Vasostrict from Endo International free of charge for use in an investigator-initiated, NIH-funded phase IIb clinical trial that is evaluating the safety and efficacy of vasopressin treatment to improve social abilities in children with ASD. The Board of Trustees of the Leland Stanford Junior University has filed patent applications related to data reviewed herein: PCT/US2019/019029 (“Methods for diagnosing and determining severity of an autism spectrum disorder”) and PCT/US2019/041250 (“Intranasal Vasopressin Treatment for Social Deficits in Children with Autism”). These patents have not been granted, nor licensed, and no author is receiving financial compensation at this time.
References
-
- Insel TR, O’Brien DJ, Leckman JF. Oxytocin, vasopressin, and autism: is there a connection? Biol Psychiatry. 1999;45:145–57. - PubMed
MeSH terms
Substances
Grants and funding
- R01 HD091972/HD/NICHD NIH HHS/United States
- HD091972/U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- HD091972/U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- W81XWH-21-1-0210/U.S. Department of Defense (United States Department of Defense)
LinkOut - more resources
Full Text Sources
Medical
